Neonatal venlafaxine discontinuation syndrome: A mini-review

European Journal of Paediatric Neurology

Volumn 21, Issue 2, 2017, Pages 264-268

  Holland, Jonathon ^a   Brown, Richard ^a  

^a PETERBOROUGH CITY HOSPITAL   (United Kingdom)

Author keywords

Abstinence; Discontinuation; Encephalopathy; Neonate; Venlafaxine; Withdrawal

Indexed keywords

ANTICONVULSIVE AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT;

AWARENESS; BRAIN DISEASE; CLINICAL DECISION MAKING; ELECTROENCEPHALOGRAPHY; FOLLOW UP; HUMAN; MYOCLONUS SEIZURE; NERVOUSNESS; OUTCOME ASSESSMENT; PLACENTA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; WITHDRAWAL SYNDROME; BRAIN DISEASES; CHEMICALLY INDUCED; FEMALE; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; SEIZURES; SUBSTANCE WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; BRAIN DISEASES; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEIZURES; SUBSTANCE WITHDRAWAL SYNDROME; VENLAFAXINE HYDROCHLORIDE;

EID: 85007557122     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2016.11.003     Document Type: Review

References (15)

1. 1 Hudak, M.L., Tan, R.C. The Committee on Drugs The Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 129 (2012), e540–560, 10.1542/peds.2011-3212.
2. 2 Sansone, R.A., Sansone, L.A., Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci 11 (2014), 37–42.
3. 3 Whyte, I.M., Dawson, A.H., Buckley, N.A., Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96 (2003), 369–374.
4. 4 Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com/mc/bnf/current/PHP2459-venlafaxine.htm. [Accessed 13 May 2016].
5. 5 UK Teratology Information Service, Use of Venlafaxine in Pregnancy. February 2016 http://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-VENLAFAXINE-IN-PREGNANCY/ [Accessed 13 May 2016].
6. 6 Holland, J., Brown, R., Babiker, S., Neonatal movement disorder and mild encephalopathy secondary to venlafaxine withdrawal: case report and literature review. (Poster Abstract). Devl Med Child Neurol, 58(S1), 2016, 20, 10.1111/dmcn.12998.
7. 7 De Moor, R.A., Mourad, L., ter Haar, J., Egberts, A.C., Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneeskd 147 (2003), 1370–1372 [article in Dutch].
8. 8 Koren, G., Moretti, M., Kapur, B., Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome?. J Obstet Gynaecol Can 28 (2006), 299–302.
9. 9 Pakalapati, R.K., Bolisetty, S., Austin, M.P., Oei, J., Neonatal seizures from in utero venlafaxine exposure. J Paediatr Child Health 42 (2006), 737–738, 10.1111/j.1440-1754.2006.00962.x.
10. 10 Rampono, J., Simmer, K., Illet, K.F., et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42 (2009), 95–100, 10.1055/s-0028-1103296.
11. 11 Boucher, N., Koren, G., Beaulac-Baillargeon, L., Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit 31 (2009), 404–409, 10.1097/FTD.0b013e3181a58fb4.
12. 12 Hoppenbrouwers, C.J., Bosma, J., Wennink, H.J., et al. Neonatal seizures on EEG after in utero exposure to venlafaxine. Br J Clin Pharmacol 70 (2010), 454–456, 10.1111/j.1365-2125.2010.03714.x.
13. 13 Haukland, L.U., Kutzsche, S., Hovden, I.A., Stiris, T., Neonatal seizures with reversible EEG changes after antenatal venlafaxine exposure. Acta Paediatr 102 (2013), e524–526, 10.1111/apa.12375.
14. 14 Ansary, A., Ibhanesebhor, S., Manjunatha, C., Myoclonic seizures in a preterm baby: is this a presentation of venlafaxine withdrawal?. Singap Med J 55 (2014), e57–59, 10.11622/smedj.2014061.
15. 15 Renoir, T., Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol, 2013, 10.3389/fphar.2013.00045.